• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Helus Pharma Inc. - Common Stock (NQ:HELP)

11.05 +0.67 (+6.45%)
Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Helus Pharma Inc. - Common Stock

< Previous 1 2 3 Next >
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints CNS Drug Development Veteran Suresh Durgam to Board of Directors
Today 9:15 EDT
Via Investor Brand Network
News headline image
Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
Today 7:30 EDT
From Helus Pharma Inc.
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Host Investor Presentation Highlighting Depression and Anxiety Treatment Programs on Oct. 21
October 08, 2026
Via Investor Brand Network
News headline image
Helus Pharma to Host Investor Presentation on October 21, 2026
October 08, 2026
From Helus Pharma Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Changes Legal Name from Cybin Inc.
October 01, 2026
Via Investor Brand Network
TinyGemsBreaks – Helus Pharma (TM) (NASDAQ: HELP) (Cboe CA: HELP) Advances HLP003 Phase 3 Program, Targets Q4 2026 Topline Data
August 14, 2026
Via Investor Brand Network
News headline image
Helus Pharma Announces Completion of Legal Name Change
October 01, 2026
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression ↗
September 24, 2026
Helus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of... 
Via MarketBeat
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Annual and Special Meeting Results, Legal Name Change Effective Oct. 1
September 23, 2026
Via Investor Brand Network
News headline image
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
September 22, 2026
From Helus Pharma
Via GlobeNewswire
NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in TD Cowen Neuropsychiatry Summit
September 22, 2026
Via Investor Brand Network
News headline image
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board ↗
September 22, 2026
Cybin (NASDAQ:HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company’s auditor,... 
Via MarketBeat
News headline image
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
September 21, 2026
CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT 
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Presents HLP003 Data From MDD Program at Psych Congress 2026
September 21, 2026
Via Investor Brand Network
News headline image
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
September 21, 2026
From Helus Pharma
Via GlobeNewswire
News headline image
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 ↗
September 21, 2026
Cybin (NASDAQ:HELP) executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright’s 28th Annual Global... 
Via MarketBeat
News headline image
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances ↗
September 20, 2026
Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter,... 
Via MarketBeat
BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Morgan Stanley Global Healthcare Conference
September 10, 2026
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
September 10, 2026
CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT. 
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in H.C. Wainwright 28th Annual Global Investment Conference
September 09, 2026
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York
September 09, 2026
CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT 
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Cantor Global Healthcare Conference
September 03, 2026
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
September 03, 2026
CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. 
From Helus Pharma
Via GlobeNewswire
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Regina Donohue Chief People Officer and Suresh Durgam to Scientific Advisory Board
August 18, 2026
Via Investor Brand Network
News headline image
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
August 18, 2026
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
August 14, 2026
From Helus Pharma
Via GlobeNewswire
News headline image
Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003 ↗
August 14, 2026
Helus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an... 
Via MarketBeat
Topics Intellectual Property
MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO to Participate in Canaccord Genuity Growth Conference
August 11, 2026
Via Investor Brand Network
News headline image
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
August 10, 2026
CEO Michael Halstead to participate in a fireside chat on Wednesday, August 12 at 12:00 p.m. EDT 
From Helus Pharma
Via GlobeNewswire
News headline image
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
August 05, 2026
Issued on behalf of Helus Pharma (Nasdaq: HELP) 
From USA News Group
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap